Exelixis EXEL Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's operating cash flow?
- Exelixis (EXEL) reported operating cash flow of $251.85M in Q1 2026.
- How has Exelixis's operating cash flow changed year-over-year?
- Exelixis's operating cash flow increased by 19.1% year-over-year, from $211.44M to $251.85M.
- What is the long-term trend for Exelixis's operating cash flow?
- Over 4 years (2021 to 2025), Exelixis's operating cash flow has grown at a 21.9% compound annual growth rate (CAGR), from $400.8M to $884.27M.
- What does operating cash flow mean?
- The net cash flow generated from the company's primary business operations.
- How do you interpret operating cash flow?
- Higher values indicate strong operational efficiency and profitability, while negative values may signal a need for external funding or operational distress.
- How does operating cash flow compare across companies?
- A fundamental metric for all public companies; biopharma peers with mature commercial products typically show strong positive cash flow.